Clinical Trial Update: High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated high-dose imatinib (Gleevec) given alone or in combination with pegylated interferon alfa-2b (Peg-Intron) and GM-CSF (sargramostim) in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Leukine (sargramostim)
• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myeloid, Chronic | Phase 3 | Status: COMPLETED